LYEL Stock Analysis: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$14.82
-0.71 (-4.57%)
▼
5d:
+9.37%
30d:
+17.34%
90d:
-15.12%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: LYEL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: LYEL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $14.82, which is considered extended relative to its 30-day fair value range of $12.90 to $14.80.
Technical Outlook: Technically, LYEL is in a strong downtrend. Immediate support is located at $13.39, while resistance sits at $17.15. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: LYEL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $37.88 (+143.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LYEL is in a strong downtrend. Immediate support is located at $13.39, while resistance sits at $17.15. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: LYEL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $37.88 (+143.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.90 -
$14.80
Company Quality Score
32/100
(SELL)
Options IV Signal
48th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
31.2%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 48th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 143.9% below Wall St target ($37.88)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$12.90 -
$14.80
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.04
(20.5%)
Support & Resistance Levels
Support Level
$13.39
Resistance Level
$17.15
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.46
Wall Street Target
$37.88
(+143.9%)
Revenue Growth (YoY)
-50.0%
Share & Embed Analysis
Last updated: August 24, 2026 9:47 AM ET
Data refreshes hourly during market hours. Next update: 10:47 AM
Data refreshes hourly during market hours. Next update: 10:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
